Home > Keywords > Thématique > Science

Science

Articles

  • Vect-Horus successfully completes the VECtoBrain project
    28 January 2019, by Jonathan NOWAK

    Ths project was supported from 2009 to 2013 by the Agence Nationale de la Recherche (ANR) BiotecS Call 2009.
    The project was coordinated by VECT-HORUS (Dr. Guillaume Jacquot) and involved the UMR7259 laboratory (CNRS and Aix-Marseille University, Director Dr Michel Khrestchatisky), the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA.
    This project also received support (label) from the EUROBIOMED Biocluster.

  • Meet Vect-Horus at TIDES Europe in Vienna from November 16th to 18th, 2022.
    16 November 2022, by Elodie DORMES

    Guillaume JACQUOT will share a presentation on “Targeted delivery of Therapeutic Oligonucleotides to CNS by systemic administration” a good opportunity for Vect-Horus to present its last results.
    Emmanuelle BETTENDORF will be there as well to assist to conferences about Emerging #Oligonuleotide Therapeutics, #Delivery Strategies for Oligonucleotides, Peptides and mRNA and meet with all actors in the field.

  • Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
    28 January 2019, by Jonathan NOWAK

    (Molino et al., 2017, The FASEB Journal)
    www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

  • mRNA Based Therapeutics poster
    3 February 2025, by Emmanuelle BETTENDORF

    Pavlo Shpak-Kraievskyi is presenting a poster on behalf of Vect-Horus at the 4th Annual mRNA-Based Therapeutics Summit Europe, taking place January 28-30 in Frankfurt, Germany.
    Effective delivery of mRNA therapeutics to the central nervous system (CNS) remains a significant challenge due to the protective blood-brain barrier (BBB). The poster, entitled “VECTrans® Technology for CNS Targeting with Lipid Nanoparticles”, outlines results from a study of VECTrans® enabling the targeted (…)

  • Vect-Horus and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)
    28 January 2019, by Jonathan NOWAK

    and publish a review article on CNS drug delivery (Vlieghe and Khrestchatisky, 2012, Med Res Rev).

  • 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
    12 April 2022, by Elodie DORMES

    Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.

  • ECMED EU-GliaPhD international conference in MALTA
    28 January 2019, by Jonathan NOWAK

    Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel Khrestchatisky will give a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.

  • Vect-Horus strengthens its scientific advisory board with the appointment of Frédéric MATONTI
    16 May 2022, by Elodie DORMES

    Vect-Horus extends its Scientific Advisory Board with the expertise of Frédéric Matonti, a Leading Ophthalmology Specialist.

  • Oligonucleotides for CNS Congress from February 22-24, 2021
    2 February 2021, by Elodie DORMES

    Dr Michel KHRESTCHATISKY will join the session dealing with “Exploring Extra-Hepatic Delivery to Relevant Targets within the CNS & Muscle” and give a talk to describe the use of VECT-HORUS “Molecular Vectors for Targeted Delivery of Oligonucleotides”.

  • Two new patents protecting VECTrans® technology issued in several major countries
    28 January 2019, by Jonathan NOWAK

    Press release Communiqué de presse
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the granting of two patents in several major countries and particularly in the United States.
    These two patents protect peptide vectors that facilitate the targeting of drugs or imaging agents to organs, including the brain. Entitled “Peptide (…)